Telitacicept, a dual inhibitor of the cytokines B-lymphocyte stimulator and a proliferation-inducing ligand, showed efficacy ...
Higher levels of antimitochondrial antibodies in patients with systemic lupus erythematosus are tied to a higher risk for ...
J&J's phase IIb JASMINE study on nipocalimab meets key endpoints in systemic lupus erythematosus, supporting plans to advance ...
Clinical Trials Arena on MSN
J&J’s Imaavy posts win in Phase II SLE trial
Imaavy will now progress to Phase III in SLE, though it will face strong competition from SLE market leader, Benlysta, if ...
Over 3.4 million people globally are affected by SLE, and it is one of the leading causes of death in young women in the US ...
In early January 2026, Johnson & Johnson reported that nipocalimab (Imaavy) met primary and key secondary endpoints in the ...
Johnson & Johnson (JNJ) announced on Tuesday that nipocalimab, its experimental therapy for an autoimmune condition called ...
Fresh off of a European approval for a subcutaneous version of Saphnelo, AstraZeneca is doubling down on the benefits of the ...
The JASMINE trial showed nipocalimab's efficacy in SLE, meeting primary and secondary endpoints, including steroid sparing ...
Low baseline 25 (OH)D levels are associated with higher mortality and cardiovascular event risks among patients with systemic lupus erythematosus (SLE), with evidence of a U-shaped relationship ...
In systemic lupus erythematosus, chronic spontaneous urticaria did not raise SLEDAI scores, but cylindruria, mucosal ulcers, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback